STOCK TITAN

Eledon Pharmaceuticals: BVF Partners reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Eledon Pharmaceuticals, Inc. (ELDN) shares are the subject of an ownership report by Biotechnology Value Fund, L.P., related funds and managers, and Mark N. Lampert, a director and officer of BVF Inc. As of September 30, 2026, Biotechnology Value Fund, L.P. reported 6,061,390 shares (7.0%), Biotechnology Value Fund II, L.P. 2,173,905 shares (2.6%), and Biotechnology Value Trading Fund OS LP 377,015 shares (0.4%). BVF Partners L.P., BVF Inc. and Lampert each may be deemed to beneficially own 8,655,393 shares (9.99%); these are overlapping attributions, not separate holdings to add together.

As of that date, 9.99% ownership blockers prohibited conversion of all Series X and Series X1 preferred shares held by the reporting persons and the Partners Managed Account, and limited exercise of 15,247,782 Pre-Funded Warrants to 2,362,111 underlying shares. The Tranche A Blocker prohibited exercise of all 5,844,153 Tranche A Warrants into shares; those warrants carry a $3.00 per-share exercise price and expire May 5, 2028.

Beneficial ownership attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert 8,655,393 shares Each may be deemed to beneficially own this amount as of September 30, 2026; attributions overlap.
Reported ownership percentage 9.99% Approximate percentage attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert as of September 30, 2026.
Biotechnology Value Fund, L.P. reported ownership 6,061,390 shares As of September 30, 2026; approximately 7.0% of the class.
Biotechnology Value Fund II, L.P. reported ownership 2,173,905 shares As of September 30, 2026; approximately 2.6% of the class.
Pre-Funded Warrants held 15,247,782 warrants As of September 30, 2026; the blocker limited exercise to 2,362,111 underlying shares.
Pre-Funded Warrant exercise limit 2,362,111 shares Maximum exercise permitted under the blocker as of September 30, 2026.
Tranche A Warrants held 5,844,153 warrants As of September 30, 2026; the blocker prohibited exercise into shares.
Tranche A Warrant exercise price $3.00 per share Tranche A Warrants expire May 5, 2028.
Series X Blocker technical
"the Series X Blocker prohibits the conversion of all"
Series X1 Blocker technical
"the Series X1 Blocker prohibits the conversion of all"
Pre-Funded Blocker technical
"the Pre-Funded Blocker limits the exercise"
Tranche A Blocker technical
"the Tranche A Blocker prohibits the exercise"
Pre-Funded Warrants financial
"15,247,782 Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Tranche A Warrants financial
"5,844,153 Tranche A Warrants"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ELDN shares did Mark N. Lampert report?

Mark N. Lampert, a director and officer of BVF Inc., may be deemed to beneficially own 8,655,393 shares, approximately 9.99% of ELDN's outstanding shares, as of September 30, 2026. The report also states that Lampert disclaims beneficial ownership of shares held by the funds and the Partners Managed Account.

What exercise limits apply to ELDN's reported warrants and preferred shares?

As of September 30, 2026, 9.99% blockers prohibited conversion of all Series X and Series X1 preferred shares held by the reporting persons and the Partners Managed Account. The Pre-Funded Blocker limited exercise of 15,247,782 Pre-Funded Warrants to 2,362,111 shares; the Tranche A Blocker barred all 5,844,153 Tranche A Warrants from exercise into shares. Tranche A Warrants are exercisable at $3.00 per share and expire May 5, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





28617K101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading